Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07123350) titled 'Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease' on Aug. 7.
Study Type: Observational
Primary Sponsor: Vanderbilt University Medical Center
Condition:
Inflammatory Bowel Disease (IBD)
Crohn&Amp
#39
s Disease (CD)
Ulcerative Colitis (UC)
Intervention:
Drug: Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
Recruitment Status: Not recruiting
Date of First Enrollment: October 1, 2025
Target Sample Size: 120
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07123350
...